Speculating. Covid ARDS treatment, if successful, demonstrates...

Speculating.
Covid ARDS treatment, if successful, demonstrates easy mode of administration (first pass to lungs) and the trial should also provide a great store of data from untreated controls, not just those treated. Including comparison and early numbers of chronic post covid survivors and diagnoses, and their post covid related chronic conditions. Also further develops the science and knowledge. “The more the inflammation, the better the treatment works” etc.

Whilst CHF & LBP are massive patient disease numbers, the current momentum and focus and knowledge growth is respiratory, and also acute severe life threatening inflammation. Both CHF & LBP imo are not quite in the same category. Acute Crohns, Ulcerative Colitis can be more acute.

Hence the progression from Covid ACUTE RDS to non-Covid Acute RDS (flu etc), and also to Covid Acute generalised multi system inflammation.
I am then postulating treatment for other very acute very severe inflammation including acute exacerbations of COPD, and maybe even Asthma. Also post massive trauma or surgery, in ICU.

And that the market for ‘basic’ or chronic (rather than acute exacerbations of chronic) treatment and improvement in exercise tolerance in COPD (chronic obstructive airways disease) - all those wheezy, coughing, short of breath, puffing and panting ex & current smokers etc, is also mind boggling numbers.

Interesting times over the next 2-3 years!